Company ProfilePremium

Alliance Healthcare Group Limited

Company Profile Analysis

Ticker: MIJ.SI

ESOMAR 23 Corporate BadgeISO Certifications Badge
Alliance Healthcare Group Limited - Company showcase

Year Founded & Workforce

1994

395 Employees

Alliance Healthcare Group Limited logo

Alliance Healthcare Group Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Alliance Healthcare Group Limited Overview

Alliance Healthcare Group is a physician-founded Singapore healthcare platform with roughly S$87m in revenue. It combines six businesses that are usually run separately: a 16-clinic "My Family Clinic" GP chain plus a medical centre; private specialist clinics in orthopaedics, ENT and general surgery; a medical third-party administrator (Alliance Medinet) that manages outpatient and specialist benefits for insurers and corporates across a partner network of more than 2,000 facilities; an HSA-licensed pharmaceutical wholesaler; a home-care and telemedicine arm (Jaga-Me, now 98.4% owned) that supports five public hospitals under the Ministry of Health's MIC@Home programme; and a small institutional health-IT business. Its core thesis is that owning both the payer-side administration and the provider-side delivery lets it steer patient volume through its own network and capture data on utilisation. The company is micro-cap (about S$37m), founder-controlled (about 68%), almost entirely domestic (98% Singapore revenue), thinly traded and uncovered by sell-side research. FY2026 brought a profit inflection.


Company's own description (paraphrased from Annual Report 2025)

The Annual Report 2025 describes Alliance as a trusted medical brand that spans GP and in-house specialist clinics, a corporate health-solutions organisation, a wholesale pharmaceutical company serving the region, and a mobile and home-care provider. It calls itself "physician-led and physician-driven". The report says the company aims to be a next-generation healthcare company that uses technology to deliver cost-effective, personalised services, and that utilisation data helps corporate clients and insurers get better value from their health spending. Its stated vision is to empower people to lead healthy lives through an integrated ecosystem of care. Its stated mission is to be a healthcare innovation company that personalises and simplifies community care delivery. In the FY2025 Chairman's Message, management describes a post-IPO "strategic pivot" away from a traditional brick-and-mortar model towards a digitally enabled platform that links self-owned and partner facilities into a single health ecosystem.

Independent characterisation

On the evidence of its segment accounts, Alliance is best understood as a Singapore managed-care administrator with a captive provider network attached, rather than as a clinic chain.

Managed healthcare solutions: (Alliance Medinet plus in-house corporate clinics) is now the largest segment by revenue (25.4% in FY2026) and by far the largest by profit. It generated S$3.25m pre-tax in FY2026, about 85% of group PBT of S$3.82m. It also carries most of the group's balance sheet: S$70.8m of S$102.8m segment assets, mainly claims receivables offset by claims payables to panel providers.

GP clinic services: (S$20.1m) and specialist care services (S$19.8m) are the provider layer. Both have thin margins, and both are sensitive to doctor retention and start-up costs.

Pharmaceutical services: (S$14.5m) is a wholesale distribution business with an overseas export component. It is shrinking (−10.6% in FY2026).

Mobile and digital health services: (Jaga-Me home care plus HeyAlly telemedicine, S$7.9m) is the main growth investment. It reached EBITDA breakeven in FY2026 for the first time since the COVID-19 boom faded.

Others: (S$2.8m) is now mostly a single institutional IT contract: the clinic management system for the Health Promotion Board's Youth Preventive Service (YHCMS).

Business and revenue model

Model elementDescriptionFY2026 revenue (SGD Mn)Share of group (%)
Fee-for-service medical servicesGP and specialist consultations, procedures, health screening, radiology39.9345.7
Managed-care / TPA servicesAdministration fees and managed-care revenue from insurers and corporates; in-house corporate clinic contracts22.1425.4
Product salesWholesale of medicines, supplements and medical devices14.5416.6
Mobile and digital servicesHome nursing and medical visits (MIC@Home), telemedicine, health screening7.909.0
Others (incl. project/IT revenue)YHCMS clinic-management system contract (S$2.7m recognised in FY2026); recognised partly over time2.843.3

Source: FY2026 results, Note 4.2 (disaggregation of revenue). In FY2026, S$1.96m of revenue was recognised over time and the balance at a point in time.

There is no subscription or licensing revenue line of material size. The IT contract revenue in "Others" behaves like a project, and SGiMED's software-as-a-service income sits in an associate, so it is not consolidated.

Value-chain position

Alliance sits in the middle of the private outpatient value chain:

Upstream: it procures pharmaceuticals and devices from principals and distributors through Alliance Pharm, which also supplies the group's own clinics.

Midstream: it delivers primary, specialist, home and tele-care through owned facilities, and contracts a panel of more than 2,000 third-party facilities (FY2026 commentary). Those include GP clinics, screening centres, specialist and TCM clinics, labs, imaging centres, a private hospital and home-care providers.

Payer interface: through Alliance Medinet it administers claims for insurers and employers, steering visits into the network at pre-agreed rates. Ecosystem visits were about 1.25m in FY2024, more than 1.45m in FY2025 and about 1.55m in FY2026 (FY2026 results, commentary).

Customer types and end-markets

Customer typeSegment(s) servedEvidence
InsurersManaged healthcareEight insurer arrangements at IPO (2019). Named partners over time include Great Eastern, AXA (now HSBC Life), QBE, Aviva (now Singlife), Cigna Europe and EQ Insurance (AR2025 milestones; SGX announcement 31 Jul 2019)
Corporate employersManaged healthcare, GP, digitalMore than 2,000 corporations served at IPO (The Edge, 24 May 2019). In-house corporate clinics for SMRT, GlobalFoundries and Marina Bay Sands (AR2025 clinic list)
Public hospitals / health clustersMobile and digital, managed healthcareMIC@Home partner for five government-restructured hospitals (FY2026 commentary); NUHS@Home external nursing contract (SGX, 8 Aug 2024)
Government agenciesOthersHealth Promotion Board YHCMS contract (FY2024 to FY2026 results)
Individual patientsGP, specialist, digital16 My Family Clinic GP outlets, Alliance Medical Centre, specialist clinics, HeyAlly app
Hospitals, pharmacies, clinics, drug manufacturers (Singapore and overseas)PharmaceuticalAR2025 Sustainability Report, "Our Business"

Strategy

Stated strategic themes (paraphrased from AR2025 Chairman's Message and FY2026 commentary)

  1. Platform pivot. The company is moving from brick-and-mortar clinics to a digitally enabled platform connecting self-owned and partner facilities into one health ecosystem for corporates, employees and individuals.

  2. Ecosystem expansion. It aims to deepen a seamless care journey from preventive care through chronic disease management, specialist treatment and post-hospital care at home, with the goal of better care at lower cost and greater access.

  3. Payer-provider integration. Through Alliance Medinet, it works with insurers, employers and providers to deliver care at competitive, predictable prices (FY2026 commentary).

  4. Home and hospital-at-home care. It is backing Jaga-Me's growth after taking ownership to 98.4%.

  5. Institutional health IT. It will build on YHCMS delivery to pursue more public-sector healthcare technology work.

  6. AI and productivity. It is investing in AI and technology to raise productivity, generate data insights and develop new business models (FY2026 commentary).

  7. Portfolio optimisation. It plans disciplined execution, including rationalising or repositioning businesses where appropriate (FY2026 commentary). The Evoque exit is the first visible application.

Initiatives in the last 24 months (Oct 2024 – Oct 2026)

InitiativeDateTypeStatus / target
Second Elite Orthopaedics clinic (Gleneagles)May 2025New clinicContributing in FY2026
Breast and General Surgery clinic (51% JV with Dr Goo Tiong Thye)Inc. Feb 2025; opened Sep 2025New specialtyContributing in FY2026
Farrer Park Hospital strategic partnership plus Home Recovery ProgrammeListed in AR2025 milestonesPayer-provider partnershipOngoing
Jaga-Me NUH palliative care MOUListed in AR2025 milestones; non-bindingPartnershipNo material FY financial impact expected
YHCMS Phases 1–2 deliveryFY2025–FY2026Institutional ITPhase 2 completed about seven months early
Jaga-Me consolidation to 98.4%30 Jun 2026OwnershipCompleted
Evoque wind-downBoard resolution FY2026; ceased 31 Jul 2026Divestment / closureIn progress
Share buybackFY2026Capital return950,200 shares for S$144,029
Dividend reinstatement and increaseAug 2025, Aug 2026Capital return0.10 cents (FY2025), then 0.52 cents proposed (FY2026)
Quality management, HR and accounting systemsFY2026Internal digitalisationCommissioned
Climate transition planDisclosed FY2024–FY2025ESGCut Scope 2 emissions 25% by FY2035 vs FY2023

Medium-term financial targets

Not publicly disclosed. The company states that it has not previously given any forecast or prospect statement (FY2026 results, Item 3). It provides no revenue, margin or return targets. The dividend payout of 29.8% for FY2026 and 30% for FY2023 suggests an informal policy of about 30%, but no formal dividend policy was identified.

Products & Services

Prices and pricing models are not publicly disclosed unless noted. Launch years come from AR2025 and the results filings.

GP clinic services

OfferingDescription / capabilitiesTarget customerLaunch / latestNotes
My Family Clinic (Anchorvale)GP clinic, Blk 326A Anchorvale RdResidents; insured and corporate members—AR2025 clinic list
My Family Clinic (Angsana Breeze @ Yishun)GP clinic, Blk 507 Yishun Ave 4As above—Group raised its stake in FY2024 for S$0.53m
My Family Clinic (Choa Chu Kang)GP clinic, Sunshine PlaceAs above1,999AR2025
My Family Clinic (Clementi)GP clinic, Casa ClementiAs above——
My Family Clinic (Clementi 325)GP clinic, Blk 325 Clementi Ave 5As aboveAcquired as Lee Clinic, 2012–2018 bandGoodwill S$596,071
My Family Clinic (Hougang Central)GP clinic, Blk 804 Hougang CentralAs above—Goodwill S$780,000
My Family Clinic (Pioneer)GP clinic, Pioneer MallAs above——
My Family Clinic (Punggol Central)GP clinic, Blk 301 Punggol CentralAs above——
My Family Clinic (Rivervale)GP clinic, Rivervale MallAs above——
My Family Clinic (Segar)GP clinic, Blk 485 Segar RdAs above——
My Family Clinic (Senja)GP clinic, Senja GrandAs above——
My Family Clinic (St George)GP clinic, 2 St George's RdAs aboveAcquired, 2012–2018 band—
My Family Clinic (Tanglin Halt)GP clinic, Blk 40 Margaret DriveAs above1994 (first clinic)—
My Family Clinic (Toa Payoh Central)GP clinic, Blk 79D Toa Payoh CentralAs above——
My Family Clinic (Woodlands)GP clinic, Woodlands MartAs above1,999—
My Family Clinic (Woodlands Glen)GP clinic, Blk 573 Woodlands Dr 16As above——
Alliance Medical Centre (Dhoby)One-stop centre at Dhoby Ghaut MRT: executive health screening (including exercise stress echocardiogram), GP primary-care hub, chronic disease management programmes, diabetic retinal photographyCorporate clients; commuters; chronic patientsJan 2024Supports the Alliance Chronic Care programme (FY2024 commentary)
Alliance RadiologyDigital X-ray, mammography, ultrasound, DEXA, AI-driven echocardiographyScreening and referral patientsJan 2024Housed in the Dhoby centre
Healthier SG participationEnrolment of residents with a family doctor under MOH's Healthier SG programmeSingapore residentsFY2023 onwardsCited as a GP growth driver in FY2025 and FY2026

Specialist care services

OfferingSpecialty / locationStatus at Oct 2026Notes
Elite Orthopaedics (Mount Elizabeth)Orthopaedics, Mount Elizabeth Medical Centre #12-10OperatingFirst orthopaedic clinic, 2012–2018 band
Elite Orthopaedics (Farrer Park)Orthopaedics, Farrer Park Hospital, Connexion #10-04OperatingAR2025 list
Elite Orthopaedics (Gleneagles)Orthopaedics, Gleneagles Medical Centre #07-09OperatingOpened May 2025
My ENT Specialist (Novena)ENT, Mount Elizabeth Novena Specialist CentreOperatingMedical director: Executive Director Dr Paul Mok
My ENT Specialist (Farrer Park)ENT, Farrer Park HospitalOperatingAR2025 list
Alliance Specialist Group (Breast and General Surgery)Breast and general surgery, Gleneagles Medical Centre #03-10; 51% owned, 49% held by Dr Goo Tiong ThyeOperatingOpened Sep 2025
Ho Kok Sun ColorectalColorectal surgery, Mount Elizabeth Medical CentreCeased 1 Jul 2026Management agreement not renewed by the principal doctor
Lim Jit Fong Colorectal CentreColorectal surgery, Gleneagles Medical CentreCeased 1 Jul 2026As above
Evoque Medical AestheticsLasers, fillers, skin boosters, body contouring; Dhoby Ghaut; 60% ownedCeased 31 Jul 2026Opened Dec 2023; continuing operating losses

Managed healthcare solutions

OfferingDescriptionCustomer
Alliance Medinet TPA / network administrationOutpatient, specialist and inpatient benefits administration; pre-agreed facility rates with a network of more than 2,000 providers (FY2026)Insurers; employers
MediNet platformProprietary claims and network-administration systemInternal and partners
SIMS (Specialist Inpatient Management System)Proprietary hospital-claims management system for insurersInsurers
Specialist Appointment Request SystemSpecialist referral and bookingMembers; insurers
Alliance iCare appMember-facing mobile applicationInsured and corporate members
Cashless arrangements with public hospitalsCashless SOC and specialist services for insured members at SingHealth, KTPH, TTSH and NUHSInsurers' policyholders
Corporate clinics (My Corporate Clinic)SMRT Medical Clinic @ Woodlands Depot; My Corporate Clinic @ GlobalFoundries; MBS-Alliance In-house Clinic (Marina Bay Sands)Large employers
Alliance Chronic Care programmeCorporate chronic disease management anchored at the Dhoby centreEmployers
Farrer Park Hospital partnershipPre-agreed, more predictable facility fees for membersInsurers; employers
Alliance Medinet (M) Sdn BhdMalaysian TPA subsidiary (scale not disclosed)Malaysian clients

Pharmaceutical services

OfferingDescriptionCustomer
Alliance Pharm wholesaleHSA-licensed wholesaler and importer of therapeutic products, controlled drugs and medical devices; licensed exporter of controlled and psychotropic drugs; quality system aligned to HSA Good Distribution PracticeClinics, hospitals, pharmacies, drug manufacturers in Singapore and overseas
Internal supplyGroup procurement for GP, specialist and home-care operationsGroup entities
Pharmaceutical logistics servicesCited as a higher-margin contributor in FY2025Third parties
Alliance Pharm (HK)Sourcing, supply and distribution of pharmaceuticals and devices; incorporated Feb 2024Regional customers

Mobile and digital health services

OfferingDescriptionCustomer
Jaga-Me home careProprietary web platform for booking home nursing, doctor and therapy visitsPatients; hospitals
MIC@HomeHospital-level care at home for five restructured hospitals (FY2026 commentary). National University Health System and Sengkang General Hospital are named (AR2025)Public hospitals
NUHS@Home external nursingContract announced 8 Aug 2024NUHS
Home Recovery ProgrammePost-discharge home recovery with Farrer Park HospitalPrivate hospital patients
Jaga-Partner Portal (JPP)Referral and care-instruction portal whitelisted by MIC@Home hospital partnersHospitals
Palliative and supportive careNon-binding MOU with National University Hospital (exact date not confirmed in sources reviewed; listed among recent milestones in AR2025)Terminally ill patients
HeyAlly app / AllyCare programmeAcute and chronic teleconsultation, second opinions, same-day medication delivery for consults before 10 pmIndividuals; corporate members
HeyAlly modulesAllyStore (health products), PayAlly (rewards points), AllyTele (video consults), digital queue ticket, AllyNews, appointments, clinic locatorConsumers
Onsite health screeningCorporate screening eventsEmployers

Others / health IT

OfferingDescriptionCustomer
YHCMSSupply, customisation and maintenance of a clinic-management system for HPB's Youth Preventive Service Division; tender won with SGiMED; Phases 1 and 2 deliveredHealth Promotion Board
Ally E-ServicesRemote queue, e-appointment, e-payment and teleconsultation tools for MFC and private clinics, built with SGiMEDPrivate clinics
Hummingbird CMS (associate, 30%)SGiMED's cloud clinic-management and EMR softwarePrivate clinics

Financial Narrative

All figures are in S$m unless stated. Sources: FY2022 press release; FY2024, FY2025 and FY2026 results; AR2025 Financial Highlights (EBITDA, owners' equity); StockAnalysis/S&P for FY2022 balance-sheet and cash-flow items not otherwise available. The company reports expenses by nature, so it does not report gross profit.

Income statement

Notes:

EBIT: is EBITDA less depreciation and amortisation. It is an analyst derivation. FY2022 D&A of S$2.80m is from S&P data.

FY2022 PBT and net profit: are rounded figures from the FY2022 press release.

FY2022 EPS: is derived as S$3.112m divided by about 206.7m shares; the reported figure was not located.

Basic and diluted EPS are identical: in every year because there are no convertible instruments.

FY2026 dividend: is a proposal subject to the 27 Oct 2026 AGM.

Margins (%)

Gross profit. This is not reported by the company. A third-party derivation by S&P Global (via StockAnalysis), which classifies part of the operating cost as "cost of revenue", gives gross profit of S$9.70m (FY2022), S$8.43m (FY2023), S$9.79m (FY2024) and S$13.26m (FY2025), and S$15.14m on a trailing-twelve-month basis to December 2025. An FY2026 figure was not available. These derived numbers are not comparable to company disclosures and should be treated as indicative only.

Revenue CAGR. FY2022 to FY2026 (4 years): 12.4%. FY2021 (S$46.42m) to FY2026 (5 years): 13.5%. Both are analyst calculations.

Cost structure

Employee benefits include fees paid to non-employee locum doctors and nurses and to contracted specialists. In FY2026, S$6.12m of professional fees were paid to related parties: entities in which subsidiary directors have interests (FY2026 results, Note 6.2).

Commentary on the income statement. The five-year arc has three phases.

  1. COVID windfall and unwind (FY2022–FY2024). FY2022 margins (EBITDA 14.7%, net 5.7%) were flattered by Jaga-Me's COVID-19 swab and vaccination work. After that work ended, and as GP COVID subsidies stopped in April 2023, EBITDA fell to S$5.0m in FY2024.

  2. Investment drag (FY2024–FY2025). At the same time, the group opened a medical centre, an aesthetics clinic, a pharmaceutical warehouse and corporate clinics. D&A rose 85% from FY2023 to FY2025 and finance costs doubled. FY2024 PBT bottomed at S$24k.

  3. Operating leverage (FY2026). Revenue grew 13.3%, but consumables rose only 0.5% because lower-margin pharmaceutical volume fell away. Finance costs fell 29.6% and EBITDA rose 41.5%. PBT more than tripled to S$3.8m despite a S$1.1m operating loss at Evoque.

Staff costs rising faster than revenue (now 58% of sales) are the main structural margin risk, and management names manpower inflation explicitly in its outlook.

Balance sheet (as at 30 June)

Notes:

FY2022 balance-sheet lines: are from S&P (StockAnalysis), except owners' equity (AR2025: S$22.219m).

FY2022 NAV per share: is derived: S$22.219m divided by 206.75m shares.

FY2024 short-term borrowings: include S$7.8m reclassified from non-current because of a covenant breach. Lease and borrowing classifications at 30 Jun 2024 follow the FY2024 announcement; finance leases of S$0.7m were inside borrowings at that date.

FY2024 goodwill and intangibles: use the restated S$6.47m. The originally reported figure was S$5.48m.

Goodwill: of S$5.19m is unchanged throughout. It is split between the My Family Clinic CGUs (S$2.61m) and Jaga-Me (S$2.58m).

Commentary on the balance sheet. Total assets doubled between FY2022 and FY2026, but almost all of the growth is receivables (+S$40.8m) matched by payables (+S$39.1m). These are the gross claim flows of the managed-care business, in which the group pays panel providers and recovers from insurers and corporates. This inflates the balance sheet and depresses asset-turnover ratios without indicating extra economic capital at risk. Credit risk, however, is real: payers' ability and timing to settle now underpin a S$52.5m receivable book, roughly 1.9 times group equity.

Excluding leases, the group has been net cash in every year. Including leases, it moved briefly into net debt in FY2024–FY2025. The FY2026 rebound in cash (+S$4.8m) came from strong operating cash flow and a refinancing in which S$7.6m of new loans were drawn and S$6.3m repaid.

Bank borrowings of S$11.0m at 30 June 2026 are mostly secured. S$8.2m is secured by a legal mortgage over the Bukit Batok head-office leasehold, a charge over shares of a subsidiary, a charge over certain financed receivables and a corporate guarantee (FY2026 results, Note 14).

Cash flow

Notes:

FY2022 figures: are from S&P.

FY2024 capex: follows the FY2025 comparative presentation (PPE S$2.43m plus intangibles S$0.99m). The original FY2024 announcement showed PPE purchases of S$4.23m, which combined both.

FY2023 capex: includes a S$0.54m advance payment for equipment.

FY2026 acquisitions: is the Jaga-Me minority buy-out. The S$1.0m Jaga-Me subscription was intra-group.

Commentary on cash flow. Operating cash flow has been positive every year, but it is volatile because of managed-care working capital. In FY2023, receivables absorbed S$10.5m and OCF fell to S$2.5m. In FY2026, payables growth (+S$7.7m) more than offset receivables growth (−S$7.1m) and OCF reached a five-year high of S$10.5m. On a lease-adjusted basis, free cash flow was negative in FY2023–FY2024. It turned clearly positive in FY2026 (S$4.8m), roughly 4.5 times the proposed S$1.08m dividend.

Return, leverage and efficiency ratios

How these were calculated:

  • All ratios are analyst calculations.

FY2022 ROA and asset turnover: use year-end assets because FY2021 total assets were not obtained.

ROIC: uses NOPAT equal to EBIT × (1 − 17%, Singapore's headline rate). Invested capital is total equity plus debt including leases, minus cash.

FY2022 interest coverage: uses S&P interest expense of S$0.23m.

Cash conversion cycle. This is not meaningful for this business and is not disclosed. The receivable and payable balances are dominated by pass-through medical claims, not trade credit on own sales. On a revenue basis, payable days have consistently exceeded receivable days by about 15–35 days. That supports the reading that the group runs a modestly negative claims-float cycle.

Commentary on ratios. FY2026 ROE of about 14% is the best since FY2022 and roughly matches the post-COVID-windfall level. Interest coverage recovered from a stressed 1.2x in FY2024, the year of the covenant breach, to 7.1x. The deterioration in asset turnover is a gross-up effect of claims receivables, not a sign of capital inefficiency.

Half-year profile: notes and sources

Sources: FY2025 and FY2026 results, Note 4.2; HY2026 results. The 2H2026 profit attributable figure is S$2,090,251.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue (SGD Mn)

54.7658.0067.9877.1187.35

Revenue growth YoY (%)

18.05.917.213.413.3

EBITDA company definition (SGD Mn)

8.045.465.046.749.54

Operating income EBIT derived (SGD Mn)

5.242.661.032.044.35

Profit before tax (SGD Mn)

5.002.160.021.173.82

Net profit total (SGD Mn)

4.302.010.351.103.48

Net profit attributable to owners (SGD Mn)

3.112.090.721.523.61

EPS basic and diluted (S cents)

1.511.020.350.741.75

Dividend per share declared for FY (S cents)

0.450.300.000.100.52

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

EBITDA margin (%)

14.689.427.428.7510.92

EBIT margin (%)

9.574.581.522.654.98

PBT margin (%)

9.133.720.031.524.37

Net margin attributable (%)

5.683.601.061.984.14

Cost line

Cost lineFY2023FY2024FY2025FY2026

Consumables and medical supplies (SGD Mn)

18.2619.7519.9020.01

Employee benefits expense (SGD Mn)

31.3338.4543.9550.87

Depreciation and amortisation (SGD Mn)

2.814.014.705.19

Other expenses (SGD Mn)

4.105.856.877.29

Finance costs (SGD Mn)

0.420.870.870.62

Employee benefits as % of revenue (%)

54.056.657.058.2

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (SGD Mn)

51.6364.9582.9091.07102.79

Cash and cash equivalents (SGD Mn)

20.7119.5518.6516.4021.16

Trade and other receivables current (SGD Mn)

11.6622.1134.0244.9952.49

Inventories (SGD Mn)

2.423.203.604.073.74

Goodwill and intangibles (SGD Mn)

6.145.606.477.227.93

Borrowings short-term (SGD Mn)

1.562.2412.324.336.37

Borrowings long-term (SGD Mn)

4.407.261.286.514.91

Lease liabilities total (SGD Mn)

2.674.297.227.006.69

Total debt incl. leases (SGD Mn)

8.6313.7920.8217.8417.98

Net cash incl. leases (SGD Mn)

12.085.76-2.17-1.443.18

Net cash excl. leases (SGD Mn)

14.7510.055.055.569.88

Trade and other payables (SGD Mn)

16.7626.3238.2548.1655.85

Equity attributable to owners (SGD Mn)

22.2222.8122.7424.3727.41

Total equity incl. NCI (SGD Mn)

23.9123.7523.0124.0627.94

Working capital (SGD Mn)

13.5514.853.4110.0112.00

NAV per share (S cents)

10.7511.0911.0411.8113.25

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (SGD Mn)

9.822.474.475.7510.48

Capex PPE plus capitalised software (SGD Mn)

0.422.303.421.632.15

Free cash flow OCF less capex (SGD Mn)

9.400.171.054.128.33

Lease payments principal and interest (SGD Mn)

1.541.962.813.293.56

FCF after lease payments (SGD Mn)

7.86-1.79-1.760.834.77

Dividends paid to shareholders (SGD Mn)

0.480.930.620.000.21

Share buybacks (SGD Mn)

0.200.170.000.000.14

Acquisitions incl. NCI buy-outs (SGD Mn)

0.720.800.530.000.07

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE on average owners' equity (%)

14.829.293.166.4713.95

ROA on average total assets (%)

8.333.450.471.263.59

ROIC NOPAT on invested capital (%)

36.7012.263.416.6514.59

Current ratio (x)

1.611.471.061.181.18

Debt incl. leases to equity (x)

0.360.580.900.740.64

Net debt to EBITDA, negative means net cash (x)

-1.50-1.050.430.21-0.33

Interest coverage EBIT to finance costs (x)

22.806.321.182.347.08

Asset turnover (x)

1.061.000.920.890.90

Receivable days on revenue (days)

78139183213219

Payable days on revenue (days)

112166205228233

Income Statement

Metric1HFY20252HFY20251HFY20262HFY2026

Revenue half-year (SGD Mn)

37.9339.1842.3345.03

Profit after tax half-year (SGD Mn)

0.071.021.312.17

Profit attributable to owners half-year (SGD Mn)

0.291.231.522.09

Revenue by Region and Revenue by Region (%)

RegionFY2023FY2024FY2025FY2026

Singapore revenue (SGD Mn)

54.2965.3074.9985.59

Others Europe and Asia Pacific revenue (SGD Mn)

3.722.682.121.76

Singapore share of revenue (%)

93.696.097.298.0

Region Margins & Growth (%)

RegionFY2024FY2025FY2026

Singapore revenue growth (%)

20.314.814.1

Others revenue growth (%)

-27.8-20.9-16.9

Segment Overview

SegmentSingaporeOthers

GP clinic services (SGD Mn)

20.100.00

Specialist care services (SGD Mn)

19.830.00

Managed healthcare solutions (SGD Mn)

22.140.01

Pharmaceutical services (SGD Mn)

12.791.76

Mobile and digital health services (SGD Mn)

7.900.00

Others (SGD Mn)

2.840.00

Share Price History

DatePrice (SGD)Source

31 May 2019 (IPO)

0.200

Offer document / The Edge

7 Jan 2025

Up to 0.120 (insider purchase price)

Simply Wall St insider record

7 Jul 2026

0.158 (52-week range 0.088–0.164)

FSMOne

24 Jul 2026

0.158 (52-week change +37.4%)

StockAnalysis

11 Sep 2026

0.188

StockAnalysis

8 Oct 2026

0.180

StockAnalysis

Valuation Snapshot

MetricValueBasis

Market capitalisation (SGD Mn)

37.2

206.87m shares

Enterprise value incl. leases (SGD Mn)

34.1

Market cap + S$17.98m debt and leases − S$21.16m cash; excludes S$0.52m NCI

P/E (x)

10.3

FY2026 basic EPS 1.75 cents

EV/EBITDA (x)

3.6

FY2026 EBITDA S$9.54m (pre-lease)

EV/Sales (x)

0.39

FY2026 revenue

P/B (x)

1.36

NAV 13.25 cents

Dividend yield (%)

2.9

0.52 cents proposed

FCF yield after leases (%)

12.8

S$4.77m / S$37.2m

Per-Share Data and Returns & Leverage Ratios (%)

MetricFY2021FY2022FY2023FY2024FY2025FY2026

Dividend per share (S cents)

0.230.450.300.000.100.52

Payout ratio of PATMI (%)

31.029.930.00.013.529.8

Capital Markets

ItemDetail

Share purchase mandate

Renewed at AGMs; the 2025 appendix letter covers it

FY2023 purchases

1,000,000 shares for S$173,960

FY2026 purchases

950,200 shares for S$144,029

Treasury shares at 30 Jun 2026

1,014,165

Moody's / S&P / Fitch ratings

None (unrated)

Borrowings due within 1 year (30 Jun 2026)

S$6.37m (secured S$4.01m; unsecured S$2.36m)

Borrowings due after 1 year (30 Jun 2026)

S$4.91m (secured S$4.16m; unsecured S$0.75m)

Lease liabilities

Current S$3.17m; non-current S$3.52m

Loans from related parties

About S$0.3m (down from S$1.0m)

Analyst Conclusions

Management guidance (FY2026 commentary, 26 Aug 2026)

Management gives no numerical guidance. Its qualitative outlook is:

  • Continued pressure from rising healthcare costs, which supports demand for Alliance Medinet's cost-managed care.

  • Commitment to Jaga-Me's growth after taking ownership to 98.4%.

  • Pursuit of more institutional health-IT work after YHCMS.

  • Rising contributions expected from the two new specialist clinics.

  • Margin pressure from manpower and operating costs, offset by AI and technology investment.

  • Macro uncertainty.

  • A focus on portfolio optimisation, including rationalising or repositioning businesses.

Consensus growth expectations: not available (no coverage).

Bull case

  1. Earnings quality is improving structurally. PBT rose to S$3.82m in FY2026, with managed care (S$3.25m) and a near-breakeven mobile and digital segment doing the work. Removing Evoque's FY2026 operating loss of about S$1.1m alone would add about 30% to FY2026 PBT in FY2027, before any growth.

  2. Mispriced cash generation. At about S$34m EV, the stock trades at 3.6x pre-lease EBITDA, and FCF after leases (S$4.8m) gives a yield of about 13%. Net cash excluding leases is S$9.9m, about 27% of market cap.

  3. Option value in home care. With 98.4% of Jaga-Me and MIC@Home now a mainstream service across five restructured hospitals, any national scale-up of hospital-at-home accrues almost entirely to AHG. The FY2026 subscription price (S$0.1525 per share) gives an inexpensive base.

Bear case

  1. Specialist attrition will cut FY2027 revenue. Two colorectal practices left on 1 Jul 2026, and Evoque closed. Specialist revenue (S$19.8m in FY2026) will lose these contributors, which are not separately quantified, and the new clinics must replace them.

  2. Working-capital and credit exposure is disproportionate to equity. Receivables of S$52.5m against equity of S$27.9m mean a single payer dispute or delay could absorb a year's profit. The FY2024 covenant breach shows how thin the buffer is.

  3. Governance and liquidity discounts persist. The founder controls about 68%, the free float is about 14%, there is no analyst coverage, the Chair and CEO roles are combined, and related-party professional fees are S$6.1m. Re-rating catalysts are scarce, and a 10% one-day fall (8 Oct 2026) shows how volatile the stock can be.

Catalysts and monitorables (next 12 months)

TimingItem
27 Oct 2026AGM; approval of the 0.52-cent dividend (payable 13 Nov 2026)
Oct 2026Annual Report 2026: audited FY2026 numbers (to confirm the unaudited figures), FY2026 headcount, shareholder statistics, remuneration bands
Feb 2027HY2027 results: first half without colorectal or Evoque; specialist segment run-rate
OngoingMobile and digital: whether positive EBITDA holds and becomes positive PBT
OngoingManaged care: receivable days (219 in FY2026) and segment margin (14.7%)
OngoingNew institutional IT contracts after YHCMS
OngoingAny further portfolio rationalisation, or new specialist recruitment
2028 horizonBoard refresh: all three independent directors reach nine years' tenure in early 2028

Analyst verdict

Alliance Healthcare Group exits FY2026 as a better business than its five-year share-price record suggests. The post-COVID reset of FY2023–FY2024 has given way to a cleaner earnings mix. Alliance Medinet's managed-care franchise is now the dominant profit pool. The home-care arm has reached EBITDA breakeven. Management has shown, for the first time, a willingness to close loss-making ventures rather than fund them indefinitely. FY2026 delivered the strongest operating cash flow in the company's listed history (S$10.5m), a lease-adjusted FCF yield in the low teens at S$0.18, ROE near 14% and a dividend payout restored to about 30%.

These positives are offset by real structural limits. The group is a Singapore-only micro-cap whose specialist revenue depends on contracted doctors who can and do leave. Its claims-driven balance sheet carries receivables nearly twice its equity. Its cost base is dominated by labour costs that are rising faster than revenue. Disclosure is adequate for a Catalist issuer but thin on client concentration, payer terms and segment KPIs, and the FY2026 numbers remain unaudited until the annual report is published.

On balance, the valuation (about 10x trailing P/E and 3.6x EV/EBITDA) already prices in a substantial discount for illiquidity and founder control. The risk-reward therefore depends on whether FY2027 can hold FY2026 earnings after the specialist exits. If the Evoque loss removal and managed-care growth offset the colorectal departures, the earnings base of about S$3.5m looks sustainable, and the stock should be judged on dividend and cash yield rather than multiple expansion. If specialist attrition spreads or claims receivables deteriorate, the thin capital buffer leaves little room for error.

Assessment: fundamentally improving, but with high company-specific risk. The HY2027 results (February 2027) are the key test of earnings durability.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAppointedBackground and education (AR2025)Committee roles

Dr Barry Thng Lip Mong

Executive Chairman and CEO; founder

6 Jun 2006

MBBS (NUS, 1991); MMed (Family Medicine) (NUS, 1998); Fellow, College of Family Physicians Singapore (2002) and Academy of Medicine Singapore (2014)

Leads the executive Sustainability Committee

Dr Mok Kan Hwei, Paul

Executive Director; Head of Specialist Care Services; Medical Director, My ENT Specialist

28 Mar 2019

MBBS (NUS, 1991); Diploma of Fellowship, Royal College of Physicians and Surgeons of Glasgow (1997); committee member, Otorhinolaryngology Residency Advisory Committee

—

Mr Wong Hin Sun, Eugene

Lead Independent Director

28 Mar 2019

Founder and MD, Sirius Venture Capital (since 2002); Chairman, Tangram Asia Capital; non-executive Deputy Chairman, NTUC LearningHub; non-executive Vice-Chairman, Japan Foods Holding; Deputy non-executive Chairman, Jason Marine Group; Lead ID, APAC Realty; board of Singapore Cruise Centre. BBA (1st class, NUS); MBA (Imperial College); Harvard OPM; CFA

Chairman, ARMC; member, NC and RC

Mr Lim Heng Chong Benny

Independent Director

28 Mar 2019

Partner, Chris Chong & C T Ho LLP; nearly 30 years in practice (funds, financial regulation, M&A). LLB and LLM (NUS)

Chairman, NC; member, ARMC and RC

Dr Leong Peng Kheong Adrian Francis

Independent Director

27 Feb 2019

More than 40 years in medicine; former Chief of Surgery and Vice Chairman of the Medical Board at NUH; former elected member of the Singapore Medical Council. MBBS (NUS, 1983); MMed (Surgery) (1988)

Chairman, RC; member, ARMC and NC

Executive Leadership Team

NameTitleWith group sinceBackground (AR2025)

Ms Karen Ji Cuihua

Chief Financial Officer

Aug 2021

Deloitte & Touche; Ministry of Health internal audit; CFO roles at other SGX-listed companies. BSc (1st class) Applied Accounting, Oxford Brookes; ISCA member

Ms Jenny Oh

Chief Operating Officer

Jan 2019

Senior management roles at insurers. Bachelor of Business, Monash

Ms Ong Kai Koon, Karen

Head of Managed Healthcare Solutions; EVP, Alliance Medinet

2017

Corporate solutions provider management. Diploma in Marketing Management; health insurance certificate

Mr Wong Chien Yeh

Head of Pharmaceutical Services

2008

Registered pharmacist. BSc (Pharmacy), NUS

Ms Chiang Wai Ming

Company Secretary

—

ACIS

“—” = not publicly disclosed.

Governance Overview

AttributeStatus

Board size

5

Independent directors

3 of 5 (60%)

Chair / CEO

Combined (Dr Thng). Mitigated by a Lead Independent Director (Mr Wong)

Committees

Audit and Risk Management (all independent); Nominating; Remuneration (all independent)

Women on board

0 of 5

Independent director tenure

All three independents appointed Feb–Mar 2019, about 7.6 years by Oct 2026

Sustainability governance

Board oversight, with an executive Sustainability Committee led by the CEO and supported by the COO and CFO. All directors completed approved sustainability training

Interested-person transactions

No IPT mandate. No IPT of S$100,000 or more in FY2025 or FY2026

Major Shareholders

HolderShares (m)Stake (%)Notes

Alpine Investment Holdings Pte Ltd

133.4564.51

Holding vehicle in which Dr Thng is reported to have a deemed interest (The Edge, Oct 2021)

Dr Barry Thng Lip Mong (direct)

8.584.15

Combined direct and deemed interest about 68.3% (The Edge, Oct 2021)

28 Holdings Pte Ltd

8.003.87

Classified as an institution by Simply Wall St

Dr Mok Kan Hwei, Paul

7.143.45

Bought 538,710 shares at up to S$0.12 on 7 Jan 2025

Lim Fong

7.133.45

Individual

Wong Chien Yeh

6.633.21

Head of Pharmaceutical Services

Yun Kok Onn

2.461.19

Individual

Ang Hao Yao

1.700.82

Individual

Competitive Landscape

Key Competitors

CompetitorSegment(s) overlappingLatest revenueRelative positioning

Raffles Medical Group (SGX: BSL)

GP, specialist, corporate health, insurance

S$765.3m FY2025 (Dec YE)

Integrated hospital plus clinic plus insurer; about 9 times AHG's revenue; net-cash balance sheet

Q&M Dental Group (SGX: QC7)

Primary-care clinic chains (dental)

S$197.2m FY2025

Larger clinic roll-up; capital-markets funded (S$130m debt issuance in 2025)

Thomson Medical Group (SGX: A50)

Specialist / private hospital

S$215.9m 1H2026 revenue; net loss S$10.2m

Hospital-anchored specialist platform

AsiaMedic (SGX Catalist)

Health screening, imaging

S$35.2m FY2025; PATMI S$2.0m

Competes with Alliance Medical Centre and Alliance Radiology

Livingstone Health (SGX Catalist)

GP and specialist clinics

S$27.6m FY2025; net profit attributable about S$0.56m

Comparable-scale multidisciplinary group (20 clinics)

Singapore Paincare Holdings (SGX Catalist)

Specialist, GP

S$26.0m FY2025 (Jun YE); loss S$4.0m

Peer in specialist roll-ups; impairment-hit

Fullerton Health (private)

Corporate health, TPA, clinics

—

Major regional corporate-health competitor

MHC Asia Group (private)

Medical TPA

—

Direct competitor of Alliance Medinet

Integrated Health Plans (IHP, private)

Medical TPA

—

Direct competitor of Alliance Medinet

Parkway / IHH Healthcare (Parkway Shenton)

GP clinics, screening, corporate health

—

Scale incumbent

Speedoc, Homage (private)

Home medical and home care

—

Direct competitors of Jaga-Me

Zuellig Pharma, DKSH

Pharmaceutical distribution

—

Far larger distributors; AHG is a niche wholesaler

“—” = not publicly disclosed.

Peer Comparison FY2026

MetricAHG FY2026Raffles Medical FY2025Q&M Dental FY2025Livingstone Health FY2025

Revenue (SGD Mn)

87.35765.30197.2027.60

Revenue growth (%)

13.31.89.29.0

Net profit attributable (SGD Mn)

3.6170.579.300.56

Net margin attributable (%)

4.19.24.72.0

Company Snapshot

$66.7M

Revenue

395

Employees

1994

Founded

Singapore

Headquarters

SWOT Analysis

Strengths

  • Managed-care franchise is now the profit engine: Segment PBT S$3.25m (FY2026), about 85% of group PBT; revenue up from S$5.5m (FY2022) to S$22.1m
  • Integrated ecosystem with growing traffic: Visits rose from 1.25m to about 1.55m (FY2024–FY2026); network of more than 2,000 facilities
  • Cash generation improved sharply: OCF of S$10.48m in FY2026 (+82%); FCF after leases of S$4.77m
  • Conservative leverage excluding leases: Net cash of S$9.9m excluding leases at 30 Jun 2026; interest cover 7.1x
  • Public-sector credentials: MIC@Home partner to five restructured hospitals; NUHS@Home contract; YHCMS Phase 2 about seven months early
  • Clean compliance record: Zero substantiated data-breach complaints, zero HSA wholesaler breaches and zero serious offences in FY2024–FY2025 (AR2025)
  • Aligned founder-owner: About 68% combined interest held by the founder-CEO; directors' share purchases (for example, Dr Mok in Jan 2025)

Weaknesses

  • Thin, volatile margins: Net margin 1.1% (FY2024) to 4.1% (FY2026); staff costs 58.2% of revenue
  • Doctor-dependent specialist revenue: Both colorectal clinics ceased on 1 Jul 2026 after principal doctors did not renew
  • Execution misses on new ventures: Evoque lost about S$1.1m in FY2026 and closed after about 2.5 years; the Dhoby medical centre diluted GP profits in FY2024–FY2025
  • Working-capital intensity: Receivables of S$52.5m (219 revenue-days) against equity of S$27.9m
  • Past covenant breach: S$7.8m reclassified to current in FY2024 (later waived)
  • Governance concentration: Combined Chair/CEO; no women on the board; related-party professional fees of S$6.1m (FY2026)
  • Illiquid stock with low visibility: Free float about 14%; 20-day average volume about 47,000 shares (Jul 2026); no analyst coverage

Opportunities

  • Hospital-at-home scale-up: Mobile and digital revenue +36.4% in FY2026; Jaga-Me goodwill model assumes 15–56% growth (FY2026 Note 11)
  • Payer cost pressure drives TPA demand: Management cites rising private healthcare costs and premiums (FY2026 commentary)
  • Institutional health IT: YHCMS revenue of S$2.7m in FY2026; management targets similar public-sector work
  • Full ownership of Jaga-Me: 98.4% effective ownership means future profits accrue almost entirely to AHG shareholders
  • Healthier SG and chronic care: GP revenue +7.2% in FY2026, partly attributed to Healthier SG
  • Capital return capacity: FY2026 dividend of S$1.08m covered about 4.4 times by FCF after leases; buyback resumed

Threats

  • Specialist talent competition: Management calls competition for specialists fierce (FY2024); two practices lost in 2026
  • Wage inflation: Employee benefits +15.7% in FY2026 against revenue +13.3%
  • Payer credit and settlement risk: Bad debts from overseas customers in FY2025 (S$0.22m); claims receivables growing faster than revenue
  • Policy dependence: The GP downturn followed the end of COVID subsidies in April 2023; MIC@Home and Healthier SG are government-designed programmes
  • Larger competitors: Raffles Medical has about S$311m of cash (Dec 2025) to fund growth; private TPAs compete for the same insurers
  • Goodwill sensitivity: Jaga-Me goodwill of S$2.58m relies on 15–56% annual growth assumptions at a 15.5% discount rate

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
May 2025Second Elite Orthopaedics clinic opens at Gleneagles; pre-setup costs taken in FY2025Expands the highest-value specialty
22 Aug 2025FY2025 results: revenue S$77.1m (+13.4%), PATMI S$1.52m (+112%), PBT S$1.17mRecovery from the FY2024 trough
22 Aug 2025First and final dividend of 0.10 cents proposed (13.5% payout) after no FY2024 dividendDividend resumes
22 Aug 2025Managed-care revenue +21.1% to S$18.4m; mobile and digital +26.1%; YHCMS revenue S$1.7mMix shift towards managed care
Sep 2025Breast and General Surgery clinic (51%) opens at GleneaglesNew specialty
8 Oct 2025Annual Report 2025 published: network of more than 1,900 facilities; 1.45m ecosystem visits; 395 full-time staffDisclosure of platform KPIs
28 Oct 2025AGM: Eugene Wong (Lead ID, ARMC Chair) and Dr Adrian Leong re-elected; PSP mandate renewedGovernance continuity
14 Nov 2025FY2025 dividend of S$206,390 paidCash return
FY2026 (about Nov 2025)YHCMS Phase 2 completed about seven months ahead of the June 2026 scheduleSupports the institutional-IT credentials management cites
FY2026On-market buyback of 950,200 shares for S$144,029First buyback since FY2023
FY20261,434,035 PSP shares vest; no awards outstanding at year-endDilution overhang removed
11 Feb 2026HY2026 results: revenue S$42.3m (+11.6%); PBT S$1.84m vs S$0.30m; PATMI S$1.52m; no interim dividendProfit inflection confirmed
FY2026Specialist revenue +24.0% to S$19.8m, from the new clinicsGrowth driver
FY2026Mobile and digital EBITDA turns positive (S$16,770) on MIC@Home volumeLosses narrowing
FY2026Evoque board resolves to cease operations; S$2.54m of shareholder loans waivedLoss-making unit exited
FY2026Deed of Payment with Evoque's 40% shareholder (Dr Sanjay Ganhasan); receivable of S$236,000Recovers part of minority share of obligations
FY2026Impairment of S$102,118 on Evoque renovation and equipmentExit cost
FY2026Bank loans of S$7.6m drawn and S$6.3m repaid; finance costs −29.6%Refinancing on better terms
30 Jun 2026Jaga-Me subscription of S$1.0m at S$0.1525 per shareJaga-Me funded
30 Jun 2026Minority buy-out of S$72,567 takes Jaga-Me to 98.4% effective ownershipFull economic capture of home care
30 Jun 2026Colorectal clinic management agreements expire without renewalLoss of two specialist practices
1 Jul 2026Both colorectal clinics cease operationsSpecialist revenue headwind in FY2027
31 Jul 2026Evoque's last day of clinic operationsExit completed
26 Aug 2026FY2026 results: revenue S$87.4m (+13.3%), PBT S$3.82m (+225%), PATMI S$3.61m (+137%), OCF S$10.5mBest profit since FY2022
26 Aug 2026Dividend of 0.52 cents proposed (S$1.08m, 29.8% payout); payable 13 Nov 2026Five-fold dividend increase
26 Aug 2026Ecosystem visits about 1.55m; partner facilities more than 2,000; AI investment flaggedPlatform KPIs
11 Sep 2026Shares close at S$0.188Re-rating after results
8 Oct 2026Shares close at S$0.180 (−10.0% on the day)Volatility in an illiquid stock
27 Oct 2026 (scheduled)AGM to approve the FY2026 dividend; books close 2 Nov 2026Upcoming catalyst

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Revenue by Region: Singapore revenue rose from SGD 54.3 Mn in FY2023 to SGD 85.6 Mn in FY2026.
Alliance Healthcare Group Limited — Revenue by Region
Series (SGD Mn)FY2023FY2024FY2025FY2026
Singapore revenue54.365.37585.6
Others Europe and Asia Pacific revenue3.72.72.11.8

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Alliance Healthcare Group: FY2026 Condensed Interim Financial Statements and Results Announcement (SGXNet, 26 Aug 2026) (links.sgx.com)
  2. Alliance Healthcare Group: FY2025 Results (SGXNet, 22 Aug 2025) (links.sgx.com)
  3. Alliance Healthcare Group: FY2024 Results (SGXNet, 27 Aug 2024) (links.sgx.com)
  4. Alliance Healthcare Group: Annual Report 2025 (SGXNet, 8 Oct 2025) (links.sgx.com)
  5. Alliance Healthcare Group: FY2022 Press Release (26 Aug 2022) (links.sgx.com)
  6. Alliance Healthcare Group: HY2026 Results (11 Feb 2026) (links.sgx.com)
  7. SGXNet announcements: EQ Insurance agreement (31 Jul 2019); Jaga-Me SGX query response (19 Dec 2019); Use of IPO proceeds (3 Jan 2020; 22 Sep 2021); NUHS@Home contract (8 Aug 2024); AGM results 2022–2025
  8. The Edge Singapore: IPO launch (24 May 2019); public tranche subscription (30 May 2019); Jaga-Me acquisition (Dec 2019); Thng stake increase (Oct 2021)
  9. BioSpectrum Asia: IPO response (30 May 2019)
  10. Asgam / AGB: Marina Bay Sands in-house clinic agreement (27 Jun 2023)
  11. StockAnalysis.com (S&P Global Market Intelligence data): MIJ income statement, balance sheet, cash flow and statistics (accessed Oct 2026)
  12. FSMOne: MIJ factsheet (Jul 2026)
  13. Simply Wall St: MIJ ownership page
  14. Raffles Medical Group: FY2025 results and media release (23 Feb 2026)
  15. Q&M Dental Group: FY2025 press release (28 Feb 2026)
  16. AsiaMedic: FY2025 results release (3 Mar 2026)
  17. Livingstone Health: FY2025 press release
  18. The Edge Singapore: Singapore Paincare FY2025 results

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.